Rise in Dehydration Incidences to Spur Multiple Electrolytes Injection Market Healthy Growth

Introduction

Fluids and minerals (such as sodium and potassium) lost due to diarrhea and vomiting are replaced with medication electrolytes. It aids in the prevention or treatment of dehydration. An adequate amount of fluids and minerals are essential for the body's optimal functioning. One such example is PLASMA-LYTE 56 and 5% Dextrose Injection. It is a Multiple Electrolytes and Dextrose Injection, Type 1, USP, which has sterile, nonpyrogenic consistency. It is generally used for fluid and electrolyte replenishment. It also acts as a caloric supply in a single-dose container for intravenous administration. 

Multiple electrolyte injection is an intravenous crystalloid solution with variable electrolyte formulations depending on the market. The solution has a composition that closely resembles the electrolyte contents, osmolality, and pH of human physiological plasma. An electrolyte imbalance can ensue if the body has too much or too little water. Electrolytes are minerals found in the blood, tissues, and other body components, and the fact that they have an electrical charge is reflected in their name.

Electrolyte Abnormalities in Children to Drive Demand for Multiple Electrolytes Injection

Multiple electrolyte injections is usually prescribed for a combination of electrolytes. Thus, it is used as a water source, calorie, electrolyte, or alkalinizing agent. An electrolyte imbalance can happen if a child becomes dehydrated. Children have a higher risk of dehydration than adults due to their smaller stature and rapid fluid and electrolyte metabolism. If a kid sweats excessively or becomes ill with severe vomiting or diarrhea, an electrolyte imbalance may necessitate medical intervention. High temperatures and urination-inducing drugs are also risk factors. 

Further, an electrolyte imbalance may be more likely in a child with an underlying health issue, such as thyroid, heart, or renal disease. Electrolyte abnormalities are particularly common in children with cancer who have had a bone marrow transplant or are taking specific chemotherapy medicines. Dehydration is a leading cause of death and illness in newborns and young children worldwide. Every year, around 760,000 children suffer from diarrheal sickness around the world. These instances are expected to boost the demand for multiple electrolyte injections during the forecast period.

Impact of COVID-19

The unexpected breakout of COVID-19 has substantially impacted several industry verticals worldwide. Global manufacturing and trade have been halted due to the pandemic. Since 2020, nearly every country has seen a significant increase in impacted cases. Furthermore, the lack of a cure or vaccine for the virus has prompted many industrial players to implement countermeasures to lessen the infection's impact on their operations. 

According to the Global Change Data Lab, an associate of the University of Oxford, the total confirmed cases of COVID-19 in the United States were over 1.79 million on June 1, 2020, and had risen to over 5.99 million by August 31, 2020. In addition, some evidence has been shown in early COVID-19 investigations that electrolyte issues, such as sodium, potassium, chloride, and calcium imbalances, may also be present when patients appear. This is expected to impact multiple electrolyte injection market growth positively.

Regional Insights

North America and Europe are the two most dominant markets for multiple electrolyte injections. The increasing prevalence of kidney and heart diseases, the rise in the launch and approval of products, and the adoption of innovative marketing strategies by market players are driving the growth of the multiple electrolyte injection market in the North American region. The presence of major market players headquartered in the US, technology adoption, and strong supply chain facilities are being accepted more readily.

Several small-scale and well-known brands have entered the Asia-Pacific electrolyte mix industry, fueling market competition. Several brands are also improving their products' overall quality and effectiveness through research and development. Furthermore, many pharma companies are expanding their product lines to get a stronger footing in the competitive electrolyte mix industry. Moreover, the lack of regulatory and cultural inhibitions and the presence of market players with established R&D facilities are augmenting the growth of the multiple electrolyte injection market in Asia-Pacific.

Key Highlights

• The global multiple electrolyte injection market was valued at USD 8,994.00 million in 2019, and it is predicted to increase at a CAGR of 7.90 % from 2021 to 2029.
• Based on type, the multiple electrolyte injection market is divided into 250 ml/bag, 500 ml/bag, and 1000 ml/bag. The 250-ml/bag type segment acquired the largest market share in 2021 and is expected to grow at a CAGR of 8.11% during the forecast period. 
• By application, the multiple electrolyte injection market is segmented into hospitals, clinics, and pharmacies. The hospitals segment pegged the largest market share in 2021, followed by the pharmacies segment.
• The multiple electrolyte injection market is geographically divided into the Americas, Europe, Asia-Pacific, and the Rest of the World. The Americas and Europe are the two major markets for multiple electrolyte injection, and the markets are predicted to grow at a CAGR of 7.91% and 8.06%, respectively.

Competitive Players

1. Baxter
2. B Braun
3. Otsuka Pharmaceutical
4. ICU Medical
5. Fresenius Kabi
6. Hospira
7. Pentagon Labs
8. VetOne
9. Dechra Pharmaceuticals
10. Jiangsu Hengrui Medicine
11. Jilin Sichang Pharmaceutical
12. Luoxin Pharmaceutical
13. Tibet Weixinkang Pharmaceutical
14. Huaren Pharmaceutical

Recent Developments

• December 2023- Baxter advanced the first intravenous (IV) bag recycling pilot for US hospitals.
• November 2023- Otsuka's U.K. subsidiary, Astex, received approval for AstraZeneca's Truqap™, a treatment for metastatic breast cancer, in the United States.
• January 2024- Fresenius signed the Zero Health Gaps Pledge to promote equitable opportunity in healthcare.

Segmentation

1. By Type
   1. 250ml/Bag
   2. 500ml/Bag
   3. 1000ml/Bag
2. By Distribution Channel
   1. Hospitals
   2. Clinics
   3. Pharmacies